Dipeptidyl peptidase-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
Chemical information and Biochemical information. The chemical information includes more than 2,700 metabolite structures with detailed metabolite descriptions, extensive chemical classifications, synthesis information and observed/calculated chemical properties. It also contains nearly 5,000 NMR, GC-MS and LC-MS spectra from more than 600 different metabolites. The biochemical information includes >1,600 protein (and DNA) sequences and >3,100 biochemical reactions that are linked to these metabolite entries. The ECMDB supports many different types of online queries including text searches, chemical structure searches, sequence similarity searches and spectral similarity searches. This makes it particularly useful for metabolomic researchers who are studying E. coli as a model organism. Secondary electrospray ionization (SESI-MS) can discriminate between eleven E. Coli strains thanks to the volatile organic compound profiling.
This increase in calcium within the cell then activates a sodium-calcium exchanger (NCX). The sodium-calcium exchanger removes one Ca2+ from the cell and introduces three Na+ into the cell. This exchange further increases the membrane potential. Calcium later reenters the cell via SERCA and calcium channels located on the cell membrane. The increase in membrane potential produced by these mechanisms, activates T-type calcium channels and then L-type calcium channels (which open very slowly). These channels allow a flow of Ca2+ into the cell, making the membrane potential even more positive. Phase 0 This is the depolarization phase. When the membrane potential reaches the threshold potential (around -20 to -50 mV), the cell begins to rapidly depolarise (become more positive). This is mainly due to the flow of Ca2+ through L-type calcium channels, which are now fully open. During this stage, T-type calcium channels and HCN channels deactivate. Phase 3 This phase is the repolarization phase. This occurs due to the inactivation of L-type calcium channels (preventing the movement of Ca2+ into the cell) and the activation of potassium channels, which allows the flow of K+ out of the cell, making the membrane potential more negative.
adenosyl radical, which converts to deoxyadenosine (AdO): classic rSAM reaction, also cogenerates methionine S-adenosyl homocysteine, releasing methyl radical methylthioadenosine (SMT), homoalanine radical
Sources: en.wikipedia.org
Daveigh Elizabeth Chase ( də-VAY; née Chase-Schwallier; July 24, 1990 – June 16, 2026) was an American actress. Chase began her acting career as a child, portraying Samantha Darko in the psychological thriller film Donnie Darko (2001) and Samara Morgan in the American remake of the horror film The Ring (2002). She also provided the English dub voice of Chihiro Ogino in the Studio Ghibli film Spirited Away (2001) and voiced Lilo Pelekai in the Disney animated film Lilo & Stitch (2002) and its related media franchise. She later took on adult roles, including in the HBO drama series Big Love (2006–2011) and independent films such as Yellow (2012) and Jack Goes Home (2016). Chase received three awards from six nominations, including an Annie Award for Outstanding Achievement for Voice Acting and an MTV Movie Award for Best Villain. Chase retired from acting in 2016 and later died on June 16, 2026 from complications associated with AIDS.
After a dispute with Yale over his forced retirement and the rights to his invention of electrospray ionization, Fenn moved to Richmond, Virginia to join Virginia Commonwealth University's (VCU) department of chemistry as an analytical chemistry professor. VCU established an engineering department in the late 1990s, and Fenn held a joint professorship between the two departments until his death. Even in his 80s, Fenn enjoyed the opportunity to be in the lab doing research, saying, "I like to mingle and exchange with the young people. It gets me out from underfoot at home."
Following Alice in Chains' extensive 1993 world tour, Staley said the band "just wanted to go into the studio for a few days with our acoustic guitars and see what happened." "We never really planned on the music we made at that time to be released. But the record label heard it and they really liked it. For us, it was just the experience of four guys getting together in the studio and making some music." Columbia Records released Alice in Chains' second acoustic-based EP, Jar of Flies, on January 25, 1994. Written and recorded in one week, Jar of Flies debuted at number one on the Billboard 200, becoming the first EP—and first Alice in Chains release—to top the charts. Paul Evans of Rolling Stone called the EP "darkly gorgeous", and Steve Huey said, "'Jar of Flies' is a low-key stunner, achingly gorgeous and harrowingly sorrowful all at once." Jar of Flies features Alice in Chains' first number-one single on the Mainstream Rock charts, "No Excuses". The second single, "I Stay Away", reached number ten on the Mainstream rock charts, while the final single "Don't Follow", reached number 25. Jar of Flies has been certified triple platinum by the RIAA, with over 2 million copies sold in the United States during its first year. Jar of Flies received two Grammy nominations, Best Hard Rock Performance for "I Stay Away", and Best Recording Package. After the release of Jar of Flies, Staley entered rehab for heroin addiction.
Aggregate widths can be determined by CP/MAS NMR developed by Innventia AB, Sweden, which also has been demonstrated to work for nanocellulose (enzymatic pre-treatment). An average width of 17 nm has been measured with the NMR-method, which corresponds well with SEM and TEM. Using TEM, values of 15 nm have been reported for nanocellulose from carboxymethylated pulp. However, thinner fibrils can also be detected. Wågberg et al. reported fibril widths of 5–15 nm for a nanocellulose with a charge density of about 0.5 meq./g. The group of Isogai reported fibril widths of 3–5 nm for TEMPO-oxidized cellulose having a charge density of 1.5 meq./g. Pulp chemistry has a significant influence on nanocellulose microstructure. Carboxymethylation increases the numbers of charged groups on the fibril surfaces, making the fibrils easier to liberate and results in smaller and more uniform fibril widths (5–15 nm) compared to enzymatically pre-treated nanocellulose, where the fibril widths were 10–30 nm.
Sources: en.wikipedia.org
ubiquitination Also ubiquitylation. The labelling of a biomolecule (often another protein) by covalently attaching a ubiquitin protein to it—generally via the formation of an amide bond between the ubiquitin's C-terminal glycine and positively charged side chains (often lysine or arginine residues) of the labelled molecule, an ATP-dependent reaction catalyzed by ubiquitin-conjugating enzymes—thus making it identifiable to molecules capable of recognizing ubiquitin epitopes. Ubiquitination is a widely used post-translational modification by which proteins are tagged; the attachment of a single ubiquitin molecule (monoubiquitination) can variously activate or inhibit a protein's activity, while the attachment of a chain of multiple consecutively linked ubiquitin molecules (polyubiquitination) commonly targets the protein for degradation by proteasomes.
These are mostly single-die LEDs used as indicators, and they come in various sizes from 1.8 mm to 10 mm, through-hole and surface mount packages. Typical current ratings range from around 1 mA to above 20 mA. LED's can be soldered to a flexible PCB strip to form LED tape popularly used for decoration. Common package shapes include round, with a domed or flat top, rectangular with a flat top (as used in bar-graph displays), and triangular or square with a flat top. The encapsulation may also be clear or tinted to improve contrast and viewing angle. Infrared devices may have a black tint to block visible light while passing infrared radiation, such as the Osram SFH 4546. 5 V and 12 V LEDs are ordinary miniature LEDs that have a series resistor for direct connection to a 5 V or 12 V supply.
Lately Chief Executive, Convention of Scottish Local Authorities. For services to Local Government. Joshua MacAlister. Chair, Independent Review of Children's Social Care and Founder, Frontline. For services to Vulnerable Children. Norman Alexander MacDonald. Lately Local Councillor, Comhairle nan Eilean Siar. For services to the communities of Uig, Isle of Lewis and the Western Isles. Charles Piers Mackesy. Artist, Illustrator and Author. For services to Art and Literature. Catherine Elizabeth Magee. Chief Executive Officer, Dyslexia Scotland. For services to People with Dyslexia. Moni Mannings. Founder, EPOC (Empowering People of Colour). For services to Cultural Philanthropy, to Business and to Charity. Dr. Kathryn Jean Marks. Deputy Director, Environment Agency. For services to Flood Risk Management and to Equality, Diversity and Inclusion. Steven David Marshall. Chief Executive Officer, The Royal Naval, Army and Air Force Institute. For services to the Armed Forces. Sophia Mary Mason. Trustee, Garfield Weston Foundation. For services to Arts Philanthropy. Ian Stuart Matthews. Portfolio Leader, Ministry of Defence. For services to Defence. Samantha Kate Mayhew. Assistant Principal, Special Educational Needs and Disabilities, Weston College. For services to Further Education. Catherine McBride. Member, Trade and Agriculture Commission. For services to Economic Commentary and Trade Policy. Jonathan Robert McGoh. Chair and Co-Founder, The Reach Foundation and Co-Founder and Trustee, Reach Academy Feltham, London Borough of Hounslow. For services to Education.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.